Moderna, Inc. (FRA:0QF)

Germany flag Germany · Delayed Price · Currency is EUR
29.53
+0.54 (1.85%)
At close: Jan 9, 2026
-30.08%
Market Cap11.52B
Revenue (ttm)1.90B
Net Income (ttm)-2.66B
Shares Outn/a
EPS (ttm)-6.86
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,828
Average Volume982
Open29.31
Previous Close28.99
Day's Range28.97 - 29.54
52-Week Range19.26 - 43.20
Betan/a
RSI61.18
Earnings DateFeb 20, 2026

About Moderna

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 5,800
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 0QF
Full Company Profile

Financial Performance

In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.

Financial numbers in USD Financial Statements

News

Life-saving therapies are being delayed as research funding dries up | Letter

Dr Carol S Leonard writes that mRNA vaccines are a way forward for those with melanoma, but hopes are dashed by financial cuts This is a critically important editorial ( The Guardian view on mRNA vacc...

2 days ago - The Guardian

Moderna just had its best day since October. Here's what's going on, and what analysts expect

Analysts pointed to an upcoming health care conference and cancer data study release as potential catalysts for Moderna's ongoing rally.

4 days ago - CNBC

Moderna Stock Fights Back Against Four‑Year Curse With 20% Blastoff And A Golden Cross

Within the first week of 2026, the S&P 500 leaderboard has already delivered a surprise. Moderna Inc (NASDAQ: MRNA) has quietly muscled its way into the top year-to-date performers, up more than 20% i...

4 days ago - Benzinga

UBS Lowers Moderna (MRNA) Price Target to $34, Rating Changed to Neutral | MRNA Stock News

UBS Lowers Moderna (MRNA) Price Target to $34, Rating Changed to Neutral | MRNA Stock News

4 days ago - GuruFocus

MRNA Crosses Above Average Analyst Target

In recent trading, shares of Moderna Inc (Symbol: MRNA) have crossed above the average analyst 12-month target price of $35.30, changing hands for $35.66/share. When a stock reaches the target an anal...

4 days ago - Nasdaq

My Top 5 Stocks to Buy in Early 2026

These stocks, ranging from technology to healthcare, could add diversification to your portfolio. Four have proven their earnings strength; the fifth makes a solid recovery story bet.

4 days ago - The Motley Fool

Moderna (MRNA) Soars 10.9%: Is Further Upside Left in the Stock?

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

4 days ago - Nasdaq

Tuesday Sector Leaders: Healthcare, Technology & Communications

In afternoon trading on Tuesday, Healthcare stocks are the best performing sector, higher by 2.1%. Within that group, Moderna Inc (Symbol: MRNA) and Qnity Electronics Inc (Symbol: Q) are two large sto...

4 days ago - Nasdaq

Moderna, Inc. (MRNA) Issues Shareholder Letter Highlighting Strategic Developments

Moderna, Inc. (MRNA) Issues Shareholder Letter Highlighting Strategic Developments

4 days ago - GuruFocus

UBS Downgrades Moderna (MRNA) Amid Revenue Concerns

UBS Downgrades Moderna (MRNA) Amid Revenue Concerns

4 days ago - GuruFocus

Moderna downgraded to neutral at UBS on questions over revenue growth

UBS downgrades Moderna (MRNA) to neutral, citing flat revenue and profitability risks. Read more here.

4 days ago - Seeking Alpha

Notable Tuesday Option Activity: AMSC, MRNA, CORZ

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in American Superconductor Corp. (Symbol: AMSC), where a total volume of 8,128 contra...

4 days ago - Nasdaq

S&P 500 Forecast: Healthcare Leads US Stocks Higher—NFP Jobs Report Looms Friday

Healthcare and materials drive gains while energy falls. Moderna surges 7% and Albemarle jumps 12%. Fed’s next move hinges on Friday’s jobs data.

5 days ago - FX Empire

America's new vaccine doctrine for children replaces data with dogma

In just a few weeks, the U.S. went from a “quiet” recalibration of a single vaccine recommendation to a wholesale retreat from the basic architecture of childhood immunization. That shift is being sol...

5 days ago - Market Watch

MRNA Stock Jumps on Global Submissions Seeking Nod for Flu Vaccine

Moderna jumps after filings seeking approval for its mRNA-1010 flu vaccine across major markets, with plans to launch the shot for older adults next year.

5 days ago - Nasdaq

Moderna (MRNA) Advances Seasonal Flu Vaccine Regulatory Submissions

Moderna (MRNA) Advances Seasonal Flu Vaccine Regulatory Submissions

6 days ago - GuruFocus

Moderna (MRNA) Seeks Approval for New Influenza Vaccine

Moderna (MRNA) Seeks Approval for New Influenza Vaccine

6 days ago - GuruFocus

Moderna (MRNA) Seeks Approval for New Flu Vaccine Targeting Older Adults

Moderna (MRNA) Seeks Approval for New Flu Vaccine Targeting Older Adults

6 days ago - GuruFocus

Moderna, Inc.: Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an u...

6 days ago - Finanz Nachrichten

Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an upda...

6 days ago - Wallstreet:Online

Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an upda...

6 days ago - Accesswire

The Guardian view on mRNA vaccines: they are the future – with or without Donald Trump | Editorial

Over the holiday period, the Guardian leader column is looking ahead at the themes of 2026. Today we examine how the White House’s war on vaccines has left the future of a key technology uncertain and...

10 days ago - The Guardian

Moderna (MRNA) Falls More Steeply Than Broader Market: What Investors Need to Know

In the closing of the recent trading day, Moderna (MRNA) stood at $30.41, denoting a -2.38% move from the preceding trading day.

11 days ago - Nasdaq

Notable Tuesday Option Activity: LLY, CRWD, MRNA

Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Eli Lilly (Symbol: LLY), where a total volume of 15,152 contracts has been traded thus ...

11 days ago - Nasdaq